Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Citalopram (AN) TM
Active ingredients: citalopram
What it is used for
Treatment of Major Depression
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 25 degrees Celsius
- Shelf lifetime is 4 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White coloured, biconvex, round shaped film coated tablets debossed with A on one side and with a score line in between 0 and 7 on the other side
Images are the copyright of the Pharmacy Guild of Australia
Food interactions
For the active ingredient citalopram
- Avoid alcohol.
- Avoid St.John's Wort.
- Take without regard to meals.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2019. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient citalopram
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
How To Deal With Depression and Sadness | THIS WAY UP
Unexplained or overwhelming sadness can be a symptom of depression. Learn more about depression, its causes, and ways to get better.
Read more on This Way Up website
Selective serotonin reuptake inhibitors (SSRIs) for depression - myDr.com.au
Selective serotonin reuptake inhibitors (SSRIs) are medicines used to treatdepression and anxiety. In fact, they are the most commonly prescribed type of antidepressant medicine in Australia.&nb
Read more on myDr website
How To Deal with Panic Attacks and Agoraphobia | THIS WAY UP
Feeling overwhelmed by panic? You may be dealing with panic attacks, panic disorder, or agoraphobia. Learn more about these conditions.
Read more on This Way Up website
Top results
Citalopram versus other antidepressants for depression | Cochrane
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms including appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, psychomotor symptoms, inappropriate guilt and morbid thoughts of death. Antidepressant drugs remain the mainstay of treatment in moderate-to-severe major depression. During the last 20 years, selective serotonin reuptake inhibitors (SSRIs) have progressively become the most commonly prescribed antidepressants. Citalopram, one of the first SSRIs introduced in the market, is the racemic mixture of S- and R-enantiomer. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with all other antidepressants in the acute-phase treatment of major depression. Thirty-seven randomised controlled trials (more than 6000 participants) were included in the present review. In terms of efficacy, citalopram was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram. In terms of side effects, citalopram was more acceptable than older antidepressants, like tricyclics. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations including differences in efficacy and side-effect profiles.
Read more on Cochrane (Australasian Centre) website
Selective serotonin reuptake inhibitors (SSRIs) for fibromyalgia | Cochrane
Researchers of the Cochrane Collaboration conducted a review of research about the effects of antidepressants classified as serotonin reuptake inhibitors (SSRIs) on fibromyalgia. After searching for all relevant studies up to June 2014, they found seven studies that compared SSRIs with a fake medication. These studies included a total of 383 people. Most participants were middle-aged women. The SSRIs that they studied were citalopram, fluoxetine and paroxetine. Five studies were each funded by pharmaceutical companies, and two studies were funded by public institutions.
Read more on Cochrane (Australasian Centre) website
Antidepressants for agitation and psychosis in dementia | Cochrane
Psychosis and agitation frequently occur in older adults with dementia. Medications are often prescribed to treat these symptoms and antidepressants are increasingly used for these symptoms. We reviewed the evidence for the effectiveness and safety of antidepressants for the treatment of agitation and psychosis in older adults with dementia. We classified antidepressants based on their mechanism of action and included studies that compared antidepressants to treatment with either placebo or other medications frequently used to manage these symptoms. A total of nine studies (including 692 individuals) were identified, four comparing selective serotonin reuptake inhibitors (SSRIs) to placebo, three comparing SSRIs to typical antipsychotics, and one study comparing SSRIs to atypical antipsychotics. One study compared the antidepressant trazodone to placebo, and two compared trazodone to haloperidol. Most of the studies included in the review were relatively small and of uncertain risk of bias due to methodological issues. The SSRIs sertraline and citalopram were associated with a modest reduction in symptoms of agitation and psychosis when compared to placebo in two studies. There were few other statistically significant differences in changes in agitation or psychosis or in most measures of medication tolerability for SSRIs or trazodone when compared to placebo or the antipsychotic haloperidol. We conclude that there is some evidence to support the use of certain antidepressants for agitation and psychosis in dementia and further studies are required to determine the effectiveness and safety of SSRIs and trazodone in managing these symptoms.
Read more on Cochrane (Australasian Centre) website
Selective serotonin reuptake inhibitors for treating people with autism spectrum disorders | Cochrane
Autism spectrum disorders (ASD) are characterised by problems with social interaction and communication, as well as repetitive behaviours and limited activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that are sometimes given to reduce anxiety or obsessive-compulsive behaviours. We found nine trials, involving 320 people, which evaluated four SSRIs: fluoxetine, fluvoxamine, fenfluramine and citalopram. Five studies included only children and four studies included only adults. One trial enrolled 149 children, but the other trials were much smaller. We found no trials that evaluated sertraline, paroxetine or escitalopram. There is no evidence to support the use of SSRIs to treat autism in children. There is limited evidence, which is not yet sufficiently robust, to suggest effectiveness of SSRIs in adults with autism. Treatment with an SSRI may cause side effects. Decisions about the use of SSRIs for established clinical indications that may co-occur with autism, such as obsessive-compulsive disorder and depression in adults or children, and anxiety in adults, should be made on a case-by-case basis.
Read more on Cochrane (Australasian Centre) website
Escitalopram versus other antidepressive agents for depression | Cochrane
Read more on Cochrane (Australasian Centre) website
Escitalopram versus other antidepressive agents for depression | Cochrane
Read more on Cochrane (Australasian Centre) website
Paroxetine versus other anti-depressive agents for depression | Cochrane
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms such as appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, inappropriate guilt and morbid thoughts of death. Although medication and psychological treatments are both effective for major depression, antidepressant drugs remain the mainstay of treatment in moderate to severe major depression. However, head-to-head comparisons of such drugs provide contrasting findings as to whether they are effective.
Read more on Cochrane (Australasian Centre) website
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) | Cochrane
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)
Read more on Cochrane (Australasian Centre) website
Ketamine and other glutamate receptor modulators for depression in adults | Cochrane
Depression is one of the most common mental disorders, estimated to affect 350 million people worldwide. Antidepressant medication tends to be given as a first treatment for people with major depression. Antidepressants are however only effective in about two out of three people. Effective alternative medications to treat depression are needed. A new group of medications is called glutamate receptor modulators. This group includes the medicine ketamine. In this review we examined the evidence for glutamate receptor modulators, including ketamine, as a treatment for depression.
Read more on Cochrane (Australasian Centre) website
Clinicians FAQ | THIS WAY UP
Do you have questions about This Way Up, and how it works? Find all the answers to our Frequently Asked Questions.
Read more on This Way Up website
